KRAS mutation is considered a key point for treatment decisions in oncology as it can predict resistance to monoclonal antibodies against epidermal growth factor receptor (EGFR) [48], restricting the use of these therapies to KRAS wild-type CRC patients [10]. This evidence concerns the gene KRAS and colorectal carcinoma.